KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $92.4 million.

  • Esperion Therapeutics' Cash & Current Investments fell 3611.88% to $92.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.4 million, marking a year-over-year decrease of 3611.88%. This contributed to the annual value of $144.8 million for FY2024, which is 7600.55% up from last year.
  • Per Esperion Therapeutics' latest filing, its Cash & Current Investments stood at $92.4 million for Q3 2025, which was down 3611.88% from $86.1 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Cash & Current Investments registered a high of $259.3 million during Q4 2021, and its lowest value of $82.2 million during Q4 2023.
  • For the 5-year period, Esperion Therapeutics' Cash & Current Investments averaged around $160.9 million, with its median value being $162.3 million (2023).
  • In the last 5 years, Esperion Therapeutics' Cash & Current Investments soared by 8263.47% in 2022 and then plummeted by 5453.82% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Cash & Current Investments (Quarter) stood at $259.3 million in 2021, then crashed by 35.66% to $166.9 million in 2022, then tumbled by 50.71% to $82.2 million in 2023, then skyrocketed by 76.01% to $144.8 million in 2024, then crashed by 36.14% to $92.4 million in 2025.
  • Its Cash & Current Investments stands at $92.4 million for Q3 2025, versus $86.1 million for Q2 2025 and $114.6 million for Q1 2025.